Type 2 diabetes is a chronic disease that happens when you have too much sugar in your bloodstream. This condition typically develops slowly, sometimes as a partial consequence of lifestyle ...

The products covered include Admelog, Lantus, Toujeo, Apidra and any biosimilar of those products that Sanofi markets in the U.S. “Insulin is life-sustaining medication and far too many Mainers ...

On counterfeits, it said, “The PPB issued a public alert on July 17,2024 following an Interpol report about falsified Ozempic pens (semaglutide) where Apidra Solostar Pens (Glulisine) had been ...

For the millions of people living with diabetes worldwide, insulin is a life-saving medication. However, rising costs for this essential treatment have sparked intense debates about affordability and ...

The new guidelines took effect on May 17. In a statement sent to newsrooms, PPB now says the pens in circulation are actually Apidra Solostar pens (glulisine), which are used to treat diabetes type 1 ...

It noted that some importers were repurposing Apidra Solostar pens (glulisine) used to treat both type 1 and type 2 diabetes and selling them as Ozempic pens. "The Pharmacy and Poisons Board "the ...

Pharmacy and Poisons Board issues warning about counterfeit Ozempic Pens. The Pharmacy and Poisons Board (PPB) has warned the public against using Ozempic Pens, also known as Semaglutide.

As of Jan. 1, 2024, Sanofi cut the price of Lantus by 78% and short-acting Apidra by 70%. The price cuts will reduce the cost of the drug for most patients at $35 through either price caps or ...

It also reduced the list price of its short-acting Apidra insulin by 70%. Meanwhile, Novo Nordisk lowered the list prices of several of its insulin vials and prefilled pens by up to 75%, as of Jan. 1.